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Abstract
In order to test the accuracy of glycated hemoglobin (HbA1c) to predict mean glycemia in HIV-infected patients, we recorded consecutive HbA1c measurements from 1238 non-HIV-infected and 112 HIV-infected patients, all devoid of any hemoglobinopathy, in a retrospective, transversal study. Mean fasting glycemia from the six previous weeks (Measured-Gly) and HbA1c-estimated glycemia [HbA1c-Gly, (1.85 x %HbA1c -4.78) mM] were compared.
Mean hemoglobin, red cell volume, serum creatinine, CD4 count, and HIV-viral load from the same period were collected in HIV-infected patients. Although
Measured-Gly was not significantly different between non-HIV-infected (6.95 ± 3.23 mM) and HIV-infected patients (6.62 ± 2.42 mM), HbA1c underestimated the mean fasting glycemia by 12.3% in HIV-infected as compared to non-HIVinfected patients (p<0.0001). The difference "Measured-Gly -HbA1c-Gly" was correlated with the red cell volume (p=0.0001) in HIV-infected patients. We then searched for the presence of sub-clinical hemolysis, a cause of both macrocytosis and reduced HbA1c levels, in HIV-infected patients. To this end, we prospectively measured serum haptoglobin in 249 consecutive samples from HIV-infected subjects without any known cause of hemolysis. A very low haptoglobin level, a marker of hemolysis, was frequent and negatively correlated with the red cell volume in these patients. Treatment with nucleoside analogueswas significantly associated with macrocytosis and low haptoglobin.
In conclusion, HbA1c could be inappropriately low in HIV-infected patients. Its underestimation of mean fasting glycemia could be due to an antiretroviralinduced sub-clinical hemolysis, but further studies are needed to explore this 
Patients and Methods
Patients
We performed a retrospective transversal study using data from 1699
consecutive HbA1c measurements performed in our Biochemistry Department . P values of <0.05 were considered significant.
Results
HbA1c underevaluated mean fasting glycemia in HIV-infected patients
Measured-Gly and HbA1c-Gly were first studied in the 1350 patients included in our retrospective study. As expected, HbA1c-Gly was significantly correlated with Measured-Gly both in non-HIV-infected (r=0.665, p<0.0001, n=1238) and in HIV-infected patients (r=0.708, p<0.0001, n=112). Despite an insignificant difference between the means of the Measured-Gly in the two groups, HbA1c
and HbA1c-Gly were significantly lower (p<0.005) in the HIV-infected patients when compared to the non-HIV group (Table 1) . Measured-Gly was slightly but significantly lower than HbA1c-Gly in the non-HIV-infected group (6.95 ± 3.23 The difference between Measured-Gly and HbA1c-Gly was positively correlated with the red cell volume
We then focused our study on the HIV-infected patients by searching for any relation between the difference « Measured-Gly -HbA1c-Gly » and clinical or biological parameters available for these patients. In order to exclude any known cause leading to HbA1c misinterpretation, we excluded subjects with Hb <10 g/l (n=2), creatininemia >160 mmol/l (n=4), treated with by dapsone (n=0), ribavirin (n=2) or pyrimethamine (n=2) (drugs that have been associated with hemolysis) or suffering from liver cirrhosis (n=1) or a hemolytic disease (n=0).
When considering the remaining group of 101 HIV-infected subjects, the analyses gave similar results to those obtained in the initial group of 112 HIVinfected patients (Tables 1 and 2 ).
In the group of 101 HIV-infected patients, the difference "Measured-GlyHbA1c-Gly" (mean 0.40 mmol/l ± 2.01) was neither correlated with age, Hb, creatininemia, CD4 count, nor with HIV RNA viral load (Table 2 ). In contrast, the difference "Measured-Gly -HbA1c-Gly" was negatively correlated with HbA1c and positively correlated with the red cell volume (Table 2) . inserm-00848103, version 1 -25 Jul 2013
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The red cell volume is negatively correlated with serum haptoglobin
We then wondered whether the positive correlation between the difference "Measured-Gly -HbA1c-Gly" and the red cell volume could be linked to a hemolytic process, through both a shortened lifespan and an increased regeneration of erythrocytes. To test this hypothesis, we took advantage of 296 consecutive samples from all the HIV-infected patients referred to our laboratory for determination of lipid profile between March and April 2005. We systematically measured serum haptoglobin, and collected the clinical and biological data. After exclusion of 47 patients for any known cause of hemolysis or renal failure (see above), we considered a group of 249 patients for our analyses. The clinical and biological data from these subjects are shown in Table 3 .
The prevalence of low haptoglobin levels (<0.5 g/l), which is a marker of hemolysis, was higher in these HIV-infected patients (54/249, 21.7%) than in all other patients referred for haptoglobin measurements in our laboratory in the same period (26/201, 12.9%, p=0.01). The red cell volume (mean 98 fl ± 11) was not correlated with Hb in the HIV-infected patients (r =0.05, p=0.43, n=249). On the other hand, the red cell volume was negatively correlated with serum haptoglobin levels (r =-0.175, p<0.01, n=249) in this population.
Macrocytosis is associated with treatment with zidovudine (ZDV), stavudine (d4T), and lamivudine (3TC)
The relation between macrocytosis (red cell volume above 100 fl) and the different treatments in this population of HIV-infected patients is complex to
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analyze since each patient is given several antiretroviral medications. However, all patients had a stable antiretroviral treatment for at least 3 months, and the duration of the total antiretroviral exposure (mean 67.8 months ± 52.1) was not related to macrocytosis (p=0.25). When considering the different pharmaceutical classes, our studies showed that the treatment with any nucleoside reverse transcriptase inhibitor (NRTI) was significantly associated with macrocytosis, and that several individual NRTI molecules were associated with macrocytosis (Table 4) . When we performed a logistic regression analysis including all the NRTIs used by more than 10 patients, only zidovudine, stavudine and lamivudine remained significantly associated with macrocytosis (Table 4) .
Treatment with lamivudine (3TC) is associated with hemolysis in the group of 249 HIV-infected patients
Considering the haptoglobin values, Table 5 showed that hemolysis, as defined by serum haptoglobin <0.5 g/l, is significantly associated with NRTI treatment (p<0.0001) and in particular, as shown by the logistic regression analysis, with the use of lamivudine. The duration of the total antiretroviral exposure (mean 67.8 months ± 52.1) was not related to hemolysis (p=0.13).
As macrocytosis has previously been shown to be associated with the use of stavudine and zidovudine, and as lamivudine is frequently associated with these two drugs, we also performed analyses grouping together stavudine and zidovudine. The results, both on macrocytosis and on hemolysis, were not significantly altered (data not shown).
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Discussion
The medical follow-up of HIV-infected patients now routinely includes the prevention, screening and monitoring of metabolic complications associated with HAART, characterized by insulin resistance, dyslipidemia and hyperglycemia. 2 Assessment of blood glucose control in patients with diabetes is based upon HbA1c measurements. 1 However, in HIV-infected patients, inaccuracy of HbA1c values has been suggested. 4 Polgreen et al. have
reported a persistent discordance between glycemias and HbA1c in four patients under HAART. 4 A hemolytic process due to a hemoglobinopathy, and/or treatment with dapsone, ribavirin or, less likely, with trimethoprimsulfamethoxazole, has been suggested. 4 As we also regularly observed such a lack of correlation between HbA1c and laboratory or self-monitoring expected glycemias in HIV-infected patients with diabetes followed in our Infectious
Diseases Department, we compared the glycemia evaluated from HbA1c (HbA1c-Gly) and the mean fasting glycemia from the six previous weeks (Measured-Gly) in HIV and non-HIV-infected patients. To calculate HbA1c-Gly, we used a formula published by Nathan et al. 5 that allows an estimation of average glycemia very similar to that based from the Diabetes Control and
Complications Trial results. 6 Indeed, HbA1c-Gly and Measured-Gly were significantly correlated in all patients and we observed only a slight overestimation of mean fasting glycemia by HbA1c (+0.2%) in non-HIV-infected patients. However, although the mean Measured-Gly was not significantly different between the two groups of patients, we found that HbA1c significantly underestimated mean fasting glycemia in HIV-infected patients. Since HbA1c is inserm-00848103, version 1 -25 Jul 2013 a time-averaged index of chronic glucose level, such a discrepancy could be due to lower non-fasting glycemia in HIV-infected patients. This hypothesis seems unlikely since several studies have reported that non-fasting postglucose load glycemia is increased preferentially to fasting glycemia in HIVinfected patients treated with HAART, [7] [8] [9] which is in accordance with a predominantly peripheral insulin resistance in these patients.
10,11
The difference "Measured-Gly -HbA1c-Gly" was positively correlated with the mean red cell volume. We wondered whether this correlation could be linked to a sub-clinical hemolytic process that could lead to a reduced level of hemoglobin glycation of young erythrocytes. Indeed, a decreased level of HbA1c can be considered as a marker of hemolysis in patients without diabetes. 12, 13 In addition, an inverse relationship between the red cell volume and HbA1c was found in two papers. 14,15 As we had previously excluded from our study patients with known causes of hemolysis, we hypothesized that the antiretroviral treatment could be involved. Indeed, we observed that hemolysis, as diagnosed by a very low haptoglobin level (<0.5 g/l), was more prevalent in the HIV-infected patients as compared to subjects referred for haptoglobin measurements in our laboratory in the same period. In addition, when 
